Healthcare Enterprise Group market a product called "Ebiox" which is one of a very few that can kill most bacteria including the MRSA superbug. HCEG has contracts with some NHS hospitals at present, but given the recent and current news and public attention, HCEG should be a good bet for a steady rise as more places seek to cut the number of casualties from this infection. HCEG also market abroad in USA, so the potential market for this unique product is massive indeed.

Well worth a punt IMHO

Check it out for yourself

Rumour of the day



Healthcare Enterprise, the AIM-listed medical products group, held steady at 1.89p, despite murmurs that it is set to disclose details of a new application for Ebiox in the US on or before its first-half results early next month. The Ebiox range comprises disinfectants used to combat hospital-acquired infections

http://www.timesonline.co.uk/newspaper/0,,2727-1308426,00.html

Quite interesting Ebiox should have an application in the US. Last week, on the Scottish news, the hospitals were discussing using a hand disinfectant sourced from the US - felt like ringing them up and suggesting they consider home grown product!! The US product looked to be serving exactly the same role as I understand Ebiox does.

If it's in The Times it must be correct. now upto 1.92p on bid

On the 9th Nov it'll be 2 months since the director dealings, perhaps then we'll have some long awaited news or confirmation of the 'the rumour'. Results are due too.

skids

Are results due soon-anybody know?? Another share that has never heard of good PR !!

Intrims were end of November last year so I assume similar for this year.

I think its worth buying for interim results in november & all the talk of MRSA superbug in news each day maybe some good news in pipeline?

The NHS will not be buying this Ebiox stuff until such time as it is shown to be better than the rival products. We know it meets all the Standards, but so does everything else (or they could not be sold on the market). If it's just the same people will not buy it unless it's cheaper. If it's better and so worth paying more for, you'd have thought there'd be some actual scientific clinically relevant evidence to prove it. There isn't. So no sales. Period.

$10 million dollar contract for the use of Ebiox in the USA


http://tinyurl.com/567hn

excellent news and bid moving up rapid.

numis morning meeting 8, nov. healthcare enterprises (1.86p) BUY target price 2.40p -us deal

This is a major deal and the implications of this deal are huge.IMHO this is just the start and based on this deal alone, SP will move up very fast.
Do your research and act before it is late. I hold shares in this company.

I think this is the best news for ages in this company, bought in this morning.
opto

Ticking up again this morning

see the bid went up to 2.0p following the announcement this morning ref Optiscope thought would post it incase anyone missed it.

Healthcare Enterprise Group PLC
10 November 2004


Healthcare Enterprise Group PLC

Optiscope Technologies Ltd Manufacturing Agreement

Optiscope time to market, accelerated through agreement with Wahl Optoparts


Healthcare Enterprise Group announces agreement with Wahl Optoparts GmbH, a
division of JENOPTIKS AG, for the development and manufacture of Optiscope, a
rigid endoscope based on proprietary technology. Optiscope is one of HCEG's key
portfolio technologies. JENOPTIKS AG is a world leader in photonics
technologies operating out of twenty countries with group sales of 3 billion.

Optiscope combines a revolutionary, patented optical design with innovative
plastic manufacturing methods and components, to produce a disposable clinical
product with no compromise to functionality. This gives Optiscope a significant
clinical advantage by removing the risk of cross contamination normally
associated with the re-use of expensive endoscopy equipment. Optiscope's
products will have high quality optics and are planned to be marketed at an
extremely attractive unit cost to hospitals, clinics and general practitioners.
In addition to the elimination of cross contamination, the low price will enable
bulk purchase, thereby streamlining procedures and reducing waiting times.

As part of this agreement, Wahl Optoparts has undertaken to perform a series of
laboratory tests on Optiscope's optic design and plans to introduce, together
with Optiscope, additional elements of its own expertise that will enhance both
the intellectual property and product functionality. It is thought that the
partnership with Wahl Optoparts will accelerate time to market for the finished
product by nearly a year. HCEG now anticipates that a commercial product will
be available for FDA inspection by mid 2005.

Optiscope is uniquely competitive in the endoscope market. The cost of a
comparable re-useable rigid endoscope is circa $3,000 per instrument. These are
frequently damaged during use, resulting in costly repairs. They also require
disinfection, decontamination, sterilisation and servicing following each
operation and, with a life span of approximately 200 operations, the estimated
cost per use is $40.

Gabriele Wahl-Multerer CEO, Wahl Optoparts GmbH, commented:

'The relationship with Optiscope provides Wahl Optoparts with an exciting
opportunity to develop our business in optical products and demonstrates our
commitment, as an OEM supplier with a closed process chain, to the international
medical market.

'Wahl's know-how and established procedures will ensure effective development
and manufacture, for example, through giving us 100% traceability throughout the
total production process. We are extremely excited to be associated with
Optiscope.'


Stuart Bruck, Executive Chairman, Healthcare Enterprise Group, commented:

'This relationship with Wahl represents a pivotal step for Optiscope and sets
out the timetable to market. Wahl, as part of the mighty JENOPTIKS, should be
viewed as major endorsement and confirms our original belief, that Optiscope has
significant market potential.

'Both Ebiox and Optiscope have received acclaim at the highest levels which will
provide HCEG shareholders with confidence in management's ability as we move to
roll out our new product portfolio.'

10 November 2004


Enquiries:

Healthcare Enterprise Group PLC 020 7351 7500
Stuart Bruck, Executive Chairman

College Hill 020 7457 2020
Nicholas Nelson/ Corinna Dorward

November 11, 2004

Smaller stock to watch



Healthcare Enterprise, the AIM-listed medical devices specialist, edged up 0.03p to 1.99p on signing a manufacturing agreement with Jenoptiks, a German company with 3 billion (2 billion) of sales. Jenoptiks will develop and make Optiscope, Healthcares disposable endoscope, which is expected to be ready for inspection by the US Food and Drug Administration by mid-2005. Numis Securities yesterday repeated its 2.4p target.

http://www.timesonline.co.uk/newspaper/0,,2727-1353271,00.html

Up again today--at last we are seeing some good results. Any trading figures due soon?

Good news about the acquisition of Crest Medical today and interim results will be out today at some point

No sooner said than out. Link to interims

http://tinyurl.com/3kxgv